Dr. Woyach on the Role of Acalabrutinib in CLL


In Partnership With:

Jennifer Woyach, MD, discusses the role of acalabrutinib in chronic lymphocytic leukemia.

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the role of acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL). 

Acalabrutinib is a second-generation BTK inhibitor and, similar to ibrutinib (Imbruvica), it binds irreversibly to BTK, says Woyach.

Although ibrutinib inhibits several proteins that are similar in structure, acalabrutinib is more selective, which may mitigate toxicity. 

According to mature results from the phase 2 ACE-CL-001 trial (NCT02029443), acalabrutinib continued to show encouraging clinical activity in patients with treatment-naïve CLL. 

At a median follow-up of 53 month​s, 86% of patients were still receiving treatment, and the event-free survival rate at 48 months was 90%, which is similar to ibrutinib, Woyach concludes.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS